INTRODUCTION {#s1}
============

Ovarian cancer (OC) is the second most common female genital tract cancer and the most lethal form of all gynecological malignancies \[[@R1]\]. Based on GLOBOCAN estimates, more than 238,700 new cases and 151,900 women died from ovarian cancer every year in worldwide \[[@R2]\]. Due to the lack of specific symptoms and efficiently prognostic biomarkers, over 75% of patients are at advanced stage of the disease (Stage III or IV) when being diagnosed \[[@R3], [@R4]\]. About 30%-40% of OC patients can survive for 5 years while 10-year survival rate is only 5%-21% \[[@R4], [@R5]\]. Therefore, efficient and reliable biomarkers for individualized prediction of treatment outcomes and prognosis in early stage of OC patients are urgently required.

Accumulating evidence has shown that inflammation plays an essential role in tumor development at different stages including initiation, promotion, malignant conversion, invasion, and metastasis. The systemic inflammation is associated with poor prognosis in most of cancers \[[@R6]--[@R8]\]. The prognostic value of systemic inflammatory response markers has received paramount attention, and a variety of blood-based parameters that reflect the status of systemic inflammation have been extensively explored as prognostic biomarkers in various cancers including OC \[[@R9]--[@R11]\]. These inflammatory markers include C-reactive protein (CRP)\[[@R12]\], platelet count \[[@R13]\], neutrophil to lymphocyte ratio (NLR)\[[@R14]\], lymphocyte to monocyte ratio(LMR)\[[@R15]\], platelet to lymphocyte ratio (PLR)\[[@R16]\] and modified Glasgow prognostic score (mGPS)\[[@R9]\].

Among these inflammatory markers, the neutrophil-to-lymphocyte ratio (NLR) has gained notable interest \[[@R14], [@R17]\]. Increasing evidence indicated that NLR had prognostic significance in patients with different cancers including cervical cancer \[[@R18], [@R19]\], breast cancer \[[@R20], [@R21]\], thyroid cancer \[[@R22]\], lung cancer \[[@R23]\], colorectal cancer \[[@R24]\], prostate cancer \[[@R25]\], hepatocellular cancer \[[@R26]\], renal cancer \[[@R27]\], gastric cancer \[[@R28]\], pancreatic cancer \[[@R29]\], esophageal cancer \[[@R30], [@R31]\] and skin cancer \[[@R32]\]. Recently, several studies have evaluated the prognostic significance of NLR in OC patients; however, the majority of these studies had relatively limited sample sizes. Moreover, some authors presented inconsistent results due to the variances in study design, sample size and patient characteristics \[[@R33]--[@R48]\]. Meta-analysis is an effectively analytic approach to pool different studies to overcome above deficiencies and to provide more reliable results. We thus conducted a systematic review and meta-analysis to reveal the prognostic value of NLR in patients with OC.

RESULTS {#s2}
=======

Selection and characteristics of included studies {#s2_1}
-------------------------------------------------

The literature retrieval procedure was illustrated in Figure [1](#F1){ref-type="fig"}. The initial search collected a total of 260 articles (258 from database search, 2 from other sources), of which 42 duplicate publications were removed. The remaining 218 articles were subjected to next evaluation. After reviewing the titles and abstracts, 192 articles were excluded as they were duplicate reports, abstracts, reviews, case reports or studies irrelevant to the current analysis. Subsequently, the full text of remaining 26 articles was carefully reviewed to assess the eligibility of these articles and 10 articles were further excluded: 1 study had significant overlap, 5 articles were abstracts without detailed data, 2 papers were not prognostic article and 2 papers lacked necessary data for estimating the HR and 95% CI or the cut-off of NLR. Finally, 16 studies were used for the meta-analysis.

![Flow chart showing the process for selecting eligible studies in the meta-analysis](oncotarget-08-68938-g001){#F1}

The main characteristics of the included studies were shown in Table [1](#T1){ref-type="table"}. Total 4,910 patients from 16 studies published between 2009 and 2016 were included in the meta-analysis \[[@R33]--[@R48]\]. Among the 16 studies, 11 studies were conducted in Asian populations \[[@R35]--[@R37], [@R39], [@R41]--[@R45], [@R47], [@R48]\] while 5 studies were performed in Caucasian population \[[@R33], [@R34], [@R38], [@R40], [@R46]\], which included the following geographical regions: USA (n=3), Poland (n=1), South Korea (n=4), China (n=6), Turkey(n=1) and Thailand (n=1). The sample sizes in each study ranged 90 to 875. All included studies investigated the prognostic value of NLR for OS \[[@R33]--[@R48]\] and 12 studies investigated the prognostic role of NLR for PFS in the meta-analysis \[[@R34], [@R36]--[@R45], [@R48]\]. The median follow-up length of the studies was 52.7 months (range 29--93.7). The cut-off values applied by the included studies varied from 2.30 to 5.25, with a mean value of 3.37. 15 of the 16 studies used multivariate analysis. The scores of study quality estimated using the Newcastle Ottawa Scale (NOS) for quality assessment ranged from 5 to 8, with a mean value of 6.56.

###### Main characteristics of all the studies included in the meta-analysis

  Study cohort                  Year   country       Ethnicity   Duration    No. patients   Age (years)   Histology    Stage   Grade   Treatment   Follow-up (momths)   Cut-off value   HR    Outcome   NOS score
  ----------------------------- ------ ------------- ----------- ----------- -------------- ------------- ------------ ------- ------- ----------- -------------------- --------------- ----- --------- -----------
  Asher V \[[@R33]\]            2011   USA           Caucasian   1988-1998   235            NR            Mixed        I-IV    1-3     S+C         60                   4               U/M   OS        8
  Badora-Rybicka A \[[@R34]\]   2016   Poland        Caucasian   2007-2013   315            54(22-77)     Epithelial   I-IV    1-3     S+C         93.7                 2.3             M     OS,PFS    6
  Cho H \[[@R35]\]              2009   South Korea   Asian       2003-2006   192            52 (NA)       Epithelial   I-IV    1-3     S+C         20.9                 2.6             U/M   OS        7
  Eo WK \[[@R36]\]              2015   South Korea   Asian       2006-2013   234            56(14-84)     Epithelial   I-IV    1-3     S+C         60                   4.28            U     OS,PFS    6
  Feng Z \[[@R37]\]             2016   China         Asian       2005-2013   875            53 (30-90)    Serous       I-IV    1-3     S+C         29                   2.6             M     OS,PFS    7
  Gungorduk K \[[@R38]\]        2015   Turkey        Caucasian   1996-2011   91             57 (32-81)    PFTC         I-IV    1-3     S+C         34                   2.7             U/M   OS,PFS    5
  Kim HS \[[@R39]\]             2015   South Korea   Asian       1997-2012   109            53 (30-86)    Clear Cell   NR      NR      S+C         46                   2.8             U/M   OS,PFS    7
  Li Z \[[@R40]\]               2017   USA           Caucasian   2000-2010   654            63 (28-93)    Epithelial   I-IV    1-3     S+C         60                   5.25            U/M   OS,PFS    8
  Miao Y \[[@R41]\]             2016   China         Asian       2005-2010   344            55 (45-84)    Epithelial   I-IV    1-3     S+C         72                   3.02            U/M   OS,PFS    6
  Paik E \[[@R42]\]             2016   Korea         Asian       2002-2012   674            51 (15-84)    Epithelial   I-IV    1-3     S+C         52.5                 3.91            U/M   OS, PFS   7
  Thavaramara T \[[@R43]\]      2011   Thailand      Asian       2004-2009   129            50 (NA)       Epithelial   I-IV    1-3     S+C         NG                   2.6             M     OS, PFS   6
  Wang Y \[[@R44]\]             2015   China         Asian       2009-2010   126            NR            Serous       I-IV    1-3     S+C         41.3                 3.77            U/M   OS,PFS    7
  Wang YQ \[[@R45]\]            2016   China         Asian       2006-2013   143            52 (NA)       Mixed        I-IV    1-3     S+C         60                   3.43            U/M   OS,PFS    5
  Williams KA \[[@R46]\]        2014   USA           Caucasian   1992-2013   519            NR            Mixed        I-IV    1-3     S+C         68                   3.6             U/M   OS        6
  Zhang WQ \[[@R47]\]           2014   China         Asian       2007-2009   80             55 (27-83)    Epithelial   I-IV    1-3     S+C         45                   3.8             U/M   OS        7
  Zhang WW \[[@R48]\]           2015   China         Asian       2000-2012   190            51 (24-76)    Mixed        I-IV    1-3     S+C         43                   3.4             U/M   OS,PFS    7

HR: hazard ratio; NOS: Newcastle Ottawa Scale; NR: not reported; S: Surgery; C: Chemotherapy; U: univariate; M: multivariate; OS: overall survival; PFS: Progression free survive; PFTC: primary fallopian tube carcinoma.

NLR and OS in OC {#s2_2}
----------------

Total 16 studies with 4,910 OC patients evaluated the prognostic significance of NLR for OS. Meta-analysis of these 16 retrospective cohorts showed that the patients with elevated NLR were associated with unfavorable OS (HR: 1.50, 95% CI: 1.27-1.77, *p* \< 0.001) (Figure [2](#F2){ref-type="fig"}). Due to the extreme heterogeneity between studies (*I^2^*: 80.2%, *P~h~* \< 0.001), we conducted subgroup analyses according to the potential confounders, such as ethnicity, sample size, histologic types, cut-off value of NLR and NOS score. Subgroup analyses by ethnicity indicated that elevated NLR predicted poor prognosis for patients in Asian populations (HR: 1.69 95%CI: 1.31-2.21, random effects), but did not have prognostic efficiency for patients in Caucasian populations (HR: 1.36, 95%CI: 0.99-1.87, random effects). Stratification by sample size, the prognostic role of elevated NLR in predicting shorter OS was obvious not only in studies with small sample size (\< 200) (HR: 2.29, 95% CI: 1.49-3.52, random effects), but also in studies with large sample (≥200) (HR: 1.23, 95% CI: 1.07-1.41, random effects). Furthermore, when analyzed based on histologic types, the data showed that elevated NLR indicated poor OS in patients with epithelial histologic types (HR: 1.28, 95% CI: 1.09-1.50, random effects) and mixed histologic types (HR: 1.93, 95% CI: 1.35-2.77, random effects). In addition, when the included cohorts were stratified by cut-off value of NLR, the data showed that the elevated NLR predicted prognosis for OC regardless of the cut-off value of NLR\<3.4 (HR: 1.30, 95% CI: 1.05-1.61, random effects) and NLR≥3.4(HR: 1.89, 95% CI: 1.35-2.65, random effects). Finally, subgroup analyses by the NOS score showed that a high NLR indicated poorer OS in OC patients for studies with both NOS score ≥7 (HR: 1.49, 95% CI: 1.24-1.68, random effects) and NOS score\< 7 (HR: 1.66, 95% CI: 1.24-2.22, random effects).

![The forest plot between elevated NLR and OS in patients with OC](oncotarget-08-68938-g002){#F2}

NLR and PFS in OC {#s2_3}
-----------------

Twelve cohorts with 3,884 subjects reported the data of relationship between NLR and PFS in patients with OC. The pooled result showed that increased NLR was significantly correlated with worse PFS (HR: 1.53, 95% CI: 1.28-1.84, *p* \< 0.001), with extreme heterogeneity (*I^2^*: 85.2%, *P~h~* \< 0.001) (Figure [3](#F3){ref-type="fig"}). We also explored the heterogeneity by conducting subgroup analyses. In the subgroup analysis based on ethnicity, an elevated NLR appeared to be a poor predictor for PFS no matter the patients were Caucasian (HR: 1.25, 95% CI: 1.10-1.42, Fixed) and Asian (HR: 1.59, 95% CI: 1.25-1.84, Random). Stratification by sample size, the obvious relationship between elevated NLR and poor PFS was found in studies with both small sample size (\< 200) (HR: 1.83, 95% CI: 1.24-2.69, random effects) and large sample (≥200) (HR: 1.35, 95% CI: 1.13-1.62, random effects). Similarly, this trend was also observed with the stratification of histology type, cut-off value of NLR, analysis method and NOS score (Table [2](#T2){ref-type="table"}).

![The forest plot between elevated NLR and PFS in patients with OC](oncotarget-08-68938-g003){#F3}

###### Summary of meta-analysis results

  Factors                           No. of studies   No. of patients   Effects model   HR(95% CL)         *P*        Heterogeneity   
  --------------------------------- ---------------- ----------------- --------------- ------------------ ---------- --------------- ----------
  **Overall survival (OS)**                                                                                                          
   Overall                          16               4910              Random          1.50 (1.27-1.77)   \< 0.001   80.2%           \< 0.001
  Ethnicity:                                                                                                                         
   Caucasian                        5                1269              Random          1.36 (0.99-1.87)   0.058      72.0%           0.006
   Asian                            11               3641              Random          1.69 (1.31-2.21)   \< 0.001   83.5%           \< 0.001
  Sample size:                                                                                                                       
   \<200                            8                1605              Random          2.29 (1.49-3.52)   \< 0.001   69.4%           0.002
   ≥200                             8                3305              Random          1.23 (1.07-1.41)   0.002      69.6%           0.002
  Histologic types:                                                                                                                  
   Epithelial                       8                2622              Random          1.28 (1.09-1.50)   0.003      71.8%           0.001
   Mixed                            8                2288              Random          1.93 (1.35-2.77)   \< 0.001   77.9%           \< 0.001
  Cut-off value:                                                                                                                     
   \<3.4                            7                2600              Random          1.30 (1.05-1.61)   0.014      60.9%           0.018
   ≥3.4                             9                2310              Random          1.89 (1.35-2.65)   \< 0.001   86.2%           \< 0.001
  NOS score:                                                                                                                         
   \<7                              7                1775              Random          1.49 (1.24-1.68)   0.005      70.7%           0.002
   ≥7                               9                3135              Random          1.66 (1.24-2.22)   0.001      84.5%           \< 0.001
  Progression free survival (PFS)                                                                                                    
   Overall                          12               3884              Random          1.53 (1.28-1.84)   \< 0.001   85.2%           \< 0.001
  Ethnicity:                                                                                                                         
   Caucasian                        3                515               Fixed           1.25 (1.10-1.42)   0.001      27.5%           0.252
   Asian                            9                3369              Random          1.59 (1.25-1.84)   \< 0.001   88.0%           \< 0.001
  Sample size:                                                                                                                       
   \<200                            6                1333              Random          1.83 (1.24-2.69)   0.002      73.1%           \< 0.001
   ≥200                             6                2551              Random          1.35 (1.13-1.62)   0.001      83.0%           \< 0.001
  Histology type:                                                                                                                    
   Epithelial                       6                2350              Random          1.32 (1.09-1.59)   0.005      83.5%           \< 0.001
   Non-epithelial                   6                1534              Random          2.07 (1.39-3.01)   \< 0.001   75.4%           0.001
  Cut-off value:                                                                                                                     
   \<3.4                            6                2408              Fixed           1.28 (1.17-1.40)   \< 0.001   29.9%           0.211
   ≥3.4                             6                1476              Random          2.09 (1.30-3.37)   \< 0.001   90.5%           \< 0.001
  Analysis method:                                                                                                                   
   Univariate                       2                377               Fixed           1.09 (1.06-1.12)   \< 0.001   0.0%            0.768
   Multivariate                     10               3507              Random          1.43 (1.19-1.71)   \< 0.001   84.4%           \< 0.001
  NOS score:                                                                                                                         
   \<7                              6                1256              Random          1.57 (1.15-2.15)   0.005      68.4%           0.007
   ≥7                               6                2628              Random          1.54 (1.18-2.01)   0.001      88.8%           \< 0.001

*P* denotes P value for statistical significance based on Z test; *P*h denotes *P* value for heterogeneity based on Q test. HR hazard ratio; CI confidence interval.

Meta-regression analysis {#s2_4}
------------------------

Heterogeneity among studies was observed in the overall comparisons as well as in the subgroup analyses. We conducted meta-regression analysis by using variables as ethnicity (Asian vs. Caucasian), sample size (\<200 vs.≥200), histologic types (Epithelial vs. Mixed), cut-off value of NLR (\<3.4 vs.≥3.4) and NOS score (\<7 vs.≥7), to investigate the potential source of heterogeneity among studies for OS and PFS. In multivariate analysis, the results showed that ethnicity (*P* = 0.744), sample size (*P* = 0.074), histologic types (*P* = 0.278), cut-off value of NLR (*P* = 0.526) and NOS score (*P* = 0.465) did not contribute to the source of heterogeneity for OS. Moreover, the data demonstrated that ethnicity (*P* = 0.884), sample size (*P* = 0.585), histologic types (*P* = 0.346), cut-off value of NLR (*P* = 0.585), analysis method (*P* = 0.839) and NOS score (*P* = 0.785) were not associated for the source of heterogeneity for PFS.

Sensitivity analysis {#s2_5}
--------------------

By omitting the included studies sequentially, a sensitivity analysis was performed to assess the influence of the each included study on the pooled HR on OS and PFS was performed. The pooled HRs for OS and PFS were not substantially change. The results showed that the pooled HRs were stable and robust. The results of the sensitivity analysis were shown in Figure [4](#F4){ref-type="fig"}.

![Sensitivity analysis of NLR on OS **(A)** and PFS **(B)** in OC patients.](oncotarget-08-68938-g004){#F4}

Publication bias {#s2_6}
----------------

Begg's funnel plot and Egger's test were performed to evaluate the publication bias of the included studies. The Begg's funnel shape of the funnel plots showed that the dots were not symmetrically distributed(Figure [5](#F5){ref-type="fig"}), and the results of Egger's test demonstrated that there was significant publication bias in OS and PFS (*P\>\|t\|* = 0.000 for OS and *P\>\|t\|* = 0.001 for PFS, respectively). The results revealed publication bias in this meta-analysis. Therefore, we further performed a "trim and fill" analysis to identify the source of the publication bias. It was estimated that there were seven unpublished studies evaluating the role of the NLR in OS and six unpublished studies evaluating the role of NLR in PFS (Figure [5](#F5){ref-type="fig"}). The recalculated results that combined estimated unpublished studies did not change significantly for OS (HR: 1.08, 95%CI: 1.05--1.12, *p* \< 0.001) and PFS (HR = 1.07, 95%CI: 1.04-1.11, *p* \< 0.001), indicated a positive outcome even though publication bias still exists.

![Funnel plot adjusted using the trim and fill method for OS **(A)** and PFS **(B)** in patients with OC. Circles: included studies. Diamonds: presumed missing studies.](oncotarget-08-68938-g005){#F5}

DISCUSSION {#s3}
==========

Nowadays, many prognostic factors have been investigated in an attempt to improve treatment outcomes in OC patients, such as age, FIGO stage, residual tumor, lymph node metastasis, vascular invasion and resection margin involvement. However, these factors have some limitations including difficulty in obtaining tumor samples, time consuming, high cost to identify, and insufficient specificity or sensitivity for specific OC, which limit their extensive application in clinical settings \[[@R4], [@R5], [@R34], [@R35]\]. Therefore, new clinical predictive and prognostic markers are required. The strong linkage between inflammation and cancer progression has been well established in the past decade \[[@R6], [@R8], [@R10]\]. Interestingly, recent studies demonstrated that inflammation-related neutrophils and immunocytes mediate the communication between tumor cells and tumor microenvironment \[[@R13], [@R49]\]. The pretreatments have become the potential attractive indicator of prognosis for estimating the inflammatory response and outcomes of cancer patients. However, these two cell types play different roles in the inflammation response and cancer progression \[[@R50]\]. Neutrophils promote the proliferation and survival and of cancer cells by collecting more inflammation mediators such as interleukin-1, interleukin-6, vascular endothelial growth factor and tumour necrosis factor, and large number of neutrophils suppress cytolytic activity of lymphocytes, natural killer cells and T-cell proliferation function \[[@R51], [@R52]\]. However, lymphocytes have a vital role in the immune defense against tumour cells, which inhibit tumor cell proliferation and metastases \[[@R53], [@R54]\]. As an indicator of concisely reflecting the balance between neutrophils and immunocytes, NLR is a promising prognostic factor \[[@R22], [@R23], [@R26]\]. Additionally, it is a convenient and cost-effective and reproducible index to measure the NLR in clinical practice, which makes NLR an attractive biomarker for OC prognostication.

Although one recent meta-analysis have reported that high NLR is associated with an adverse OS and EDS in patients with gynecologic malignancies \[[@R55]\], OC has not been discussed emphatically and additional original studies with larger sample sizes have been published since then \[[@R40], [@R42], [@R44], [@R47]\], which led to its limitations. To provide a more precise assessment of the prognostic role of NLR for patients with OC, we performed a comprehensive meta-analysis by including the most recent and relevant articles. In the present study, 16 studies with 4,910 patients were included to calculate pooled HR. The results demonstrated that elevated pretreatment NLR was significantly related to poor OS and PFS in patients with OC. These findings are similar to the previous meta-analyzes, which also evaluated the prognostic value of NLR in patients with other malignancies \[[@R11], [@R14]--[@R17], [@R19], [@R21]--[@R24], [@R27], [@R28], [@R30], [@R31], [@R56]\] or gynecologic cancers. Due to the extreme heterogeneity between studies, subgroup analyses by ethnicity, sample size, histologic types, primary treatment, cut-off value of NLR, analysis method and NOS score did not show obviously significant change in the main results. Moreover, our meta-regression analysis showed that none of the variables listed above contributed to the heterogeneity. Furthermore, in terms of the correlations between NLR and clinicopathological characteristics, we did not conduct quantitative synthesis because of a relatively small amount of studies and sample size. Because of these deficiencies, although we are able to conclude that the pooled estimate of available studies indicates that a higher NLR is associated with a poor OC prognosis, whether the NLR can serve prospectively as a clinical marker of prognosis will need further investigation. In addition, the publication bias was not significant, indicating that the results of our meta-analysis are reliable. To the best of our knowledge, this is the first PROSPERO meta-analysis exploring the prognostic effects of increased NLR in OS and PFS in patients with OC.

This meta-analysis has several limitations that should be acknowledged. First, a large part of included studies were retrospective analysis and thus more susceptible to the bias in data selection. Second, the patients in most of included publications were from Asian ethnicity, which may cause selection bias for general population. Third, some studies included all pathological types of OC patients, which may cause heterogeneity and interfere with the execution of subgroup analysis and meta-regression. Fourth, the cut-off values for determining elevated NLR in each individual study were inconsistent, which may cause the heterogeneity to some extent. Finally, some studies provided the corresponding HRs but their 95% CIs could only be retrieved from univariate analysis or calculated from Kaplan-Meier curves rather than from multivariate analysis, which may impair the accuracy of the pooled estimates.

In conclusion, our meta-analysis demonstrated that elevated NLR by pretreatment was closely associated with poor survival outcome in OC patients. However, attention should be paid cautiously due to the limitations listed above. To better understand the role of NLR in the prognosis of OC patients, more large-scale and well-designed investigations should be conducted.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

The protocol of this review was registered with PROSPERO (No. CRD 42016052250) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). This analysis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). We conducted thorough literature search using the PubMed, Embase and Cochrane Library for related articles that evaluated the prognostic value of NLR for ovarian cancer. The literature search was last updated on January 31, 2017. The following medical subject headings (MeSH) and keywords employed in the literature search included: ('ovarian neoplasms' OR 'ovarian carcinoma' OR 'ovarian tumor' OR 'ovarian cancer') AND ('NLR' OR 'neutrophil to lymphocyte ratio' OR 'neutrophil-to-lymphocyte ratio' OR 'neutrophil lymphocyte ratio') AND ('prognosis' OR 'prognostic' OR 'survival' OR 'outcome' OR 'mortality'). There were no restrictions in language or publication date. In addition to the literatures searched from the above sources, the articles listed in the reference lists of the reviewed articles were also manually reviewed to obtain additional eligible studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Selection criteria studies included in the meta-analysis need to meet the following criteria: (1) evaluated the prognostic value of NLR for OC; (2) patients with a pathologically confirmed diagnosis of OC; (2) the value of NLR was acquired from a peripheral blood before treatment; (3) HRs and 95% CIs for NLR in OS and (or) PFS were reported, or the data sufficient to estimate the HR and 95% CIs in studies; (4) the cut-off value of NLR was clearly reported. A study must meet all four inclusion criteria for inclusion. The exclusion criteria were: (1) letters, conference abstracts or review articles; (2) animal studies, non-clinical studies or case reports; (3) studies had overlapping or duplicate data; (4) no access to the full text for quality assessment and insufficient data to estimate HRs and 95% CIs; (4) did not present the cut-off value for elevated NLR.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Eligible publications were reviewed by two investigators independently (Q Zhou and Z He) and the relevant data were extracted in a standardized table. The following data was extracted: surname of the first author's surname, publication year, study country, ethnicity, duration, sample size, subtype of OC, tumor stage, tumor grade, treatment method, cut-off value defining elevated NLR and HRs with corresponding 95% CIs for PFS/RFS and(or) OS. The disagreements were resolved by consulting the third investigator (Li Hong).

The quality of each included study was assessed independently by two investigators assessed according to the Newcastle-Ottawa Scale (NOS) (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>) \[[@R57]\]. The NOS consists of three parameters of quality: selection (0-4 points), comparability (0-2 points), and outcome assessment (0-3 points). The maximum possible score is 9 points and NOS scores ≥7 are considered as high-quality studies. In the case of conflicting evaluations, a third investigator (Li Hong) was consulted, and disagreement was resolved by multilateral discussion.

Statistical analysis {#s4_4}
--------------------

All data were analyzed using STATE 12.0 software (State Corporation, College Station, TX, USA), and all P values were two-sided. HRs and 95% CIs for OS and PFS were directly obtained from individual articles or calculated from indirect data according to the methods illustrated by Tierney et al \[[@R58]\]. When analyzing the relationship between NLR and clinicopathological factors, odds ratios (OR) and 95% CI were synthesized as the effective value. The heterogeneity among studies was estimated with the χ2-based Q test and Higgins'*I^2^* statistic. A *p*-value \< 0.1 for the Q-test or *I^2^*\>50% indicated significant heterogeneity, and the random-effects model was used, otherwise, the fixed-effects model was used. Sources of inter-study heterogeneity were explored using subgroup analysis. Sensitivity analyses were conducted to evaluate the stability of the results. Publication bias of literatures was evaluated using Begg's funnel plot and Egger's test.
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